MSB0254 / Transcenta - LARVOL DELTA

A Study of MSB0254 Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=25 | Terminated | Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Mar 2024 ➔ Jun 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2023 ➔ Jun 2022; Sponsor Decision

Metastases • Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors. (ASCO 2022) - P1 | "MSB0254 demonstrated a manageable safety profile and preliminary antitumor activity in patients with advanced solid tumors. 16mk/kg Q2W is recommended as RP2D. 20mg/kg Q3W is still under investigation."

Clinical • P1 data • PK/PD data • Anemia • Dyslipidemia • Endocrine Cancer • Fatigue • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Hypertriglyceridemia • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • KDR

Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting (PRNewswire) - "Transcenta Holding Limited...announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology ('2022 ASCO Annual Meeting'). The abstracts are named 'A Phase I Study of TST001, a High Affinity Humanized Anti-CLDN18.2 Monoclonal Antibody, in Combination with Capecitabine and Oxaliplatin (CAPOX) as a First Line Treatment of Advanced G/GEJ Cancer' and 'A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MSB0254 in Chinese Solid Tumor Patients' respectively."

P1 data • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. (PubMed, Biochem Biophys Res Commun) - "The VEGFR2 monoclonal antibody could inhibit the angiogenesis and tumor growth of GBM by blocking the signaling pathway mediated by VEGFR2. It may become a new supplementary treatment for GBM."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • Transplantation • CD34 • MMP2 • MMP9

A Study of MSB0254 Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.; Trial completion date: Aug 2021 ➔ Mar 2024; Trial primary completion date: Aug 2021 ➔ Dec 2023

Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Phase I Study of MSB0254 Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.

Clinical • New P1 trial